This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shimizu, W. Articles by Shimomura, K. Search for Related Content PubMed PubMed Citation Articles by Shimizu, W. Articles by Shimomura, K. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB EPINEPHRINE NICOTINAMIDE

(Circulation. 1998;97:1581-1588.)
© 1998 American Heart Association, Inc.

Clinical Investigation and Reports

Improvement of Repolarization Abnormalities by a K⁺ Channel Opener in the LQT1 Form of Congenital Long-QT Syndrome

Wataru Shimizu, MD; Takashi Kurita, MD; Kiyotaka Matsuo, MD; Kazuhiro Suyama, MD; Naohiko Aihara, MD; Shiro Kamakura, MD; Jeffrey A. Towbin, MD; ; Katsuro Shimomura, MD

From the Division of Cardiology, Department of Internal Medicine, National Cardiovascular Center, Osaka, Japan (W.S., T.K., K.M., K. Suyama, N.A., S.K., K. Shimomura), and the Little Frank Abercrombie Section of Cardiology, Department of Pediatrics and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Tex (J.A.T.)

Correspondence to Wataru Shimizu, MD, Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501-1787. E-mail shimizu{at}mmrl.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—This study used monophasic action potential (MAP) to examine the effect of nicorandil, a K⁺ channel opener, on repolarization abnormalities induced by epinephrine in the LQT1 form of congenital long-QT syndrome in which the KvLQT1 mutation underlies the defect in the channel responsible for the slowly activating component of the delayed rectifier potassium current.

Methods and Results—MAPs were recorded simultaneously from two or three sites on the right ventricular and left ventricular endocardium in 6 patients with a congenital form of LQT1 syndrome with KvLQT1 defect (17 sites) and 8 control patients (24 sites). In LQT1 patients, epinephrine infusion prolonged the QT interval and 90% MAP duration (MAPD₉₀) and increased the dispersion of MAPD₉₀. Epinephrine also induced early afterdepolarizations (EADs) as well as ventricular premature complexes (VPCs) in 2 of the 6 patients. Nicorandil during epinephrine infusion abbreviated the QT interval and MAPD₉₀, decreased the dispersion of MAPD₉₀, and abolished the EADs as well as the VPCs in 1 patient. Addition of propranolol completely reversed the effect of epinephrine in prolonging the QT interval and MAPD₉₀ and increasing the dispersion and eliminated the EADs and VPCs in another patient. In control patients, the effect of epinephrine and that of additional nicorandil and propranolol on repolarization parameters were much less than in the LQT1 patients.

Conclusions—Our results suggest that nicorandil, a K⁺ channel opener, improves repolarization abnormalities in the LQT1 form of congenital long-QT syndrome with KvLQT1 defect.

Key Words: long-QT syndrome • potassium • receptors, adrenergic, beta • depolarizing • action potentials

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Recent genetic linkage analyses have identified three forms of congenital LQTS caused by mutations in ion channel genes located on chromosomes 3, 7, and 11.^{1 2 3} Chromosome 3–linked LQT3 is associated with mutations in SCN5A, a gene that is related to inactivation of the sodium channel,¹ whereas chromosome 11–linked LQT1 and chromosome 7–linked LQT2 are associated with mutations in KvLQT1 and HERG that are linked to defects in the channel responsible for the I_Ks^{4 5} and the I_Kr⁶, respectively. The direct link of mutated genes to dysfunction of ion channels appears to lend some support to genetically defined therapy of congenital forms of LQTS. Schwartz and coworkers⁷ showed that sodium channel block with mexiletine is much more effective in abbreviating QT interval in LQT3 patients (those manifesting the sodium channel defect) than in LQT2 patients. Exogenously administered potassium has been reported to correct repolarization abnormalities in LQT2 patients (those with the potassium channel defect).⁸

Thus, we hypothesized that K⁺ channel openers could increase outward potassium current to improve repolarization abnormalities in a congenital form of chromosome 11–linked LQT1 syndrome in which the KvLQT1 mutation is believed to underlie the defect in the channel responsible for I_Ks. To test this hypothesis, we recorded MAP and examined the effect of intravenous nicorandil, a K⁺ channel opener, on repolarization abnormalities induced by epinephrine infusion in the LQT1 form of congenital LQTS.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Subjects
The study population consisted of 6 patients with the congenital form of chromosome 11–linked LQT1 syndrome and 8 control patients.

All 6 patients with the congenital form of LQTS were genotyped as chromosome 11–linked LQT1 syndrome with KvLQT1 defect; these included 3 female and 3 male patients 6 to 42 years old (mean, 24±15 years) (Table 1). Three patients (patients 1, 2, and 3) were family members. The other 3 patients (patients 4, 5, and 6) had family members with the congenital form of LQTS, which was defined according to the new diagnostic criteria of Schwartz et al.⁹ Five patients had a history of stress-induced syncope, and TdP was documented in 4 patients. One patient had occasional palpitations. They had a mean QT_c interval of 517±26 ms¹ (range, 480 to 560 ms^1/2), which was unrelated to antiarrhythmic agents, electrolyte abnormalities, or any other causes leading to QT prolongation. All 6 patients had broad-based prolonged T waves consistent with the ECG pattern reported by Moss et al¹⁰ in LQT1 syndrome (Fig 1).

View this table: [in this window] [in a new window]   Table 1. Clinical Characteristics of 6 LQT1 Patients and 8 Control Patients

View larger version (50K): [in this window] [in a new window]   Figure 1. Twelve-lead ECG demonstrating broad-based prolonged T-wave pattern and marked QT prolongation (QTc=560 ms1/2) in patient with congenital form of LQT1 syndrome with KvLQT1 defect (patient 1).

Eight control patients with concealed Wolff-Parkinson-White syndrome were also studied after successful radiofrequency catheter ablation for accessory atrioventricular connections. These were 2 female and 6 male patients 15 to 46 years old (mean, 35±10 years) with normal QT intervals (QT_c, 416±12 ms^1/2) (Table 1).

Electrophysiological Studies
All protocols were reviewed and approved by our Ethical Review Committee, and written informed consent was obtained from all patients and/or their families. Electrophysiological studies were performed in the nonsedated, postabsorbed state in all but 2 patients with congenital LQT1 syndrome (patients 1 and 3), who received diazepam (0.3 mg/kg) as sedation. All antiarrhythmic medications were discontinued for at least five drug half-lives.

Two 6F or 7F MAP catheters (MAP-pacing combination catheter, EP Technologies Inc) were introduced through a femoral vein and advanced into the right ventricle under fluoroscopic guidance to record the right ventricular MAPs. Another 6F or 7F MAP catheter was also introduced through a femoral artery and advanced into the left ventricle to record the LV MAP in all patients. A standard 6F bipolar electrode catheter with 10-mm interelectrode spacing (USCI Inc) was positioned in the right atrial appendage for atrial pacing.

MAP Recordings
MAPs were recorded simultaneously from two or three sites on the right ventricular and LV endocardium in each patient by the contact electrode technique described previously (a total of 17 recording sites in 6 patients with congenital LQT1 syndrome; a total of 24 recording sites in 8 control patients).^{11 12 13 14 15 16} MAP signals amplified and filtered at a frequency of 0.05 to 400 Hz, 12 surface ECG leads, and radial artery pressure were recorded simultaneously by a computerized multichannel system (EPLab, Quinton Electrophysiology Corp), which allowed 32 simultaneous tracings to be printed on a strip-chart recorder (paper speed from 25 to 200 mm/s) (Hewlett Packard, Laser Jet III).¹⁷ Data were stored on optical disks for subsequent reproduction. MAPs were obtained during both sinus rhythm and constant atrial pacing at a CL of 600 ms after placement of the catheter electrode in a position providing continuous recordings with a stable amplitude, smooth configuration, and isopotential diastolic baseline (phase 4). Once the contact catheter was stabilized, MAPs could be recorded continuously from the same endocardial site for long periods without additional catheter manipulation.

EADs were defined as depolarizing afterpotentials that interrupted or delayed repolarization of the action potential.¹³ MAPD₉₀ was determined, which included EADs if present. The dispersion of MAPD₉₀ was defined as the difference between the longest and the shortest MAPD₉₀ in each patient. Because the MAP recordings were obtained simultaneously from the right and left ventricles in all patients, the dispersion of MAPD₉₀ included both the right ventricular and LV values. The QT interval was defined as the time between QRS onset and the point at which the line of maximal downslope of the T wave (or the late component of the T wave, if present) crossed the baseline before the isoelectric TP interval.^{18 19}

Protocol
Constant right atrial pacing (CL, 600 ms) was performed with 2-ms rectangular stimuli at twice diastolic threshold delivered from a programmable stimulator (SEC-3102, Nihon Kohden Inc.). Recordings of MAP in the control state were obtained during constant atrial pacing for at least 3 minutes until the MAP duration reached a new steady state.²⁰ The mean of MAPD₉₀ and QT interval of more than three consecutive beats during constant atrial pacing were used for analysis.

Epinephrine Infusion
After the MAP recordings at the control state, epinephrine was infused at a constant rate of 0.1 µg · kg^-1 · min^-1 in patients of both groups. After a steady state was achieved, MAP recordings during constant atrial pacing (CL, 600 ms) were obtained as described above. The ability of epinephrine infusion to induce ventricular arrhythmias spontaneously was assessed during sinus rhythm.

Nicorandil Injection
Next, nicorandil (0.1 mg/kg) was injected for 3 minutes during continuous epinephrine infusion in patients of both groups. MAP recordings during constant atrial pacing (CL, 600 ms) were obtained 5 minutes after the completion of nicorandil injection, and the effect of nicorandil on MAP parameters was investigated. The effect of nicorandil in suppressing any ventricular arrhythmias induced by epinephrine was examined.

Propranolol Injection
In patients of both groups, propranolol (0.1 mg/kg) was injected for 5 minutes during continuous epinephrine infusion 20 minutes after the completion of nicorandil injection. MAP recordings during constant atrial pacing (CL 600 ms) were obtained 5 minutes after the completion of propranolol injection. The effects of propranolol on MAP parameters and in suppressing any ventricular arrhythmias was examined.

Statistical Analysis
Data are reported as mean±SD. Repeated-measures ANOVA followed by Scheffé's test was used to compare measurements made before and after serial drug administration. Student's t test for unpaired data was used to compare differences between LQT1 patients and control patients. A value of P<.05 was regarded as significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Sinus Cycle Length and Systolic Blood Pressure
Epinephrine significantly shortened the sinus cycle length both in patients with congenital LQT1 syndrome and in control patients (P<.0005 versus control state). Injection of nicorandil during epinephrine infusion did not change the sinus cycle length in patients of either group, whereas addition of propranolol during epinephrine infusion significantly prolonged it (P<.0005 versus nicorandil). Epinephrine significantly increased the systolic blood pressure during constant atrial pacing (CL, 600 ms) in patients of both groups (LQT1 patients, P<.001; control patients, P<.05 versus control state). Neither nicorandil nor addition of propranolol during epinephrine infusion changed the systolic blood pressure in patients of either group (Table 2).

View this table: [in this window] [in a new window]   Table 2. Changes of SCL and SBP During Atrial Pacing (600 ms)

MAPD₉₀
The MAPD₉₀ was significantly longer in patients with congenital LQT1 syndrome (n=17) than in control patients (n=24) during constant atrial pacing at the control state (314±35 versus 243±12 ms; P<.0005). In LQT1 patients, epinephrine markedly prolonged the MAPD₉₀ to 347±48 ms (P<.0005 versus control state) (Figs 2B, 3B, and 4A). Injection of nicorandil during epinephrine infusion significantly abbreviated the MAPD₉₀ to 328±38 ms (P<.005 versus epinephrine) (Figs 2C, 3C, and 4A). Addition of propranolol during epinephrine infusion completely reversed the effect of epinephrine in prolonging the MAPD₉₀ (315±32 ms, P<.05 versus nicorandil) (Figs 2D, 3D, and 4A). In control patients, epinephrine also prolonged the MAPD₉₀ to 249±14 ms (P<.0005 versus control state). However, the prolongation of MAPD₉₀ in control patients was much smaller than that in LQT1 patients (difference in the mean MAPD₉₀ before and after epinephrine, 33 versus 6 ms). Injection of nicorandil and addition of propranolol during epinephrine infusion did not change the MAPD₉₀ in control patients (nicorandil, 248±13 ms; propranolol, 246±13 ms) (Fig 4B).

View larger version (18K): [in this window] [in a new window]   Figure 2. Recordings of MAP during constant atrial pacing (CL, 600 ms) in control state, during epinephrine infusion (0.1 µg · kg-1 · min-1), after nicorandil injection (0.1 mg/kg) during epinephrine, and after addition of propranolol injection (0.1 mg/kg) during epinephrine in patient with congenital form of LQT1 syndrome (patient 1). Shown are ECG leads V3, V5, and MAP recorded simultaneously from right ventricular outflow tract (RVOT), RV anterior wall (RVant), and LV lateral wall (LVlat). B, Epinephrine induced EAD in RVOT MAP (arrow), prolonged QT interval and MAPD90 in all sites, and increased dispersion of MAPD90. C, Nicorandil abbreviated QT interval and MAPD90 in all sites and decreased dispersion of MAPD90, although EAD was not eliminated. D, Addition of propranolol abolished EAD and completely reversed effects of epinephrine to control level. Numbers in each MAP recording show MAPD90, and those at bottom of MAP recordings show dispersion of MAPD90.

View larger version (18K): [in this window] [in a new window]   Figure 3. Recordings of MAP during constant atrial pacing (CL, 600 ms) in control state, during epinephrine infusion (0.1 µg · kg-1 · min-1), after nicorandil injection (0.1 mg/kg) during epinephrine, and after addition of propranolol injection (0.1 mg/kg) during epinephrine in patient with congenital form of LQT1 syndrome (patient 6). Shown are ECG leads V1, V3, and MAP recorded simultaneously from right ventricular outflow tract (RVOT), RV septum (RVsep), and LV lateral wall (LVlat). B, Epinephrine induced EAD in LVlat MAP (arrow), prolonged QT interval and MAPD90 in all sites, and increased dispersion of MAPD90 dramatically. C, Nicorandil eliminated EAD, shortened QT interval and MAPD90 in all sites, and decreased dispersion of MAPD90. D, Addition of propranolol completely reversed effects of epinephrine to control level. Numbers in each MAP recording show MAPD90, and those at bottom of MAP recordings show dispersion of MAPD90.

View larger version (29K): [in this window] [in a new window]   Figure 4. Plots of changes in MAPD90 during constant atrial pacing (CL, 600 ms) in control state, during epinephrine infusion (Epin, 0.1 µg · kg-1 · min-1), after nicorandil injection (0.1 mg/kg) during epinephrine (Nic+Epin), and after addition of propranolol injection (0.1 mg/kg) during epinephrine (Prop+Epin) in patients with congenital form of LQT1 syndrome (17 recording sites) (A) and control patients (24 recording sites) (B).

Dispersion of MAPD₉₀
There was no significant difference in the dispersion of MAPD₉₀ between patients with congenital LQT1 syndrome (n=6) and control patients (n=8) in the control state (26±8 versus 26±6 ms). In LQT1 patients, epinephrine increased the dispersion of MAPD₉₀ to 45±13 ms (P<.01 versus control state) (Figs 2B, 3B, and 5A). Injection of nicorandil during epinephrine infusion decreased the dispersion to 26±7 ms (P<.01 versus epinephrine) (Figs 2C, 3C, and 5A). Addition of propranolol during epinephrine infusion further decreased it to 17±8 ms, although this difference did not reach statistical significance (Figs 2D, 3D, and 5A). In control patients, the dispersion of MAPD₉₀ did not change during the entire protocol (epinephrine, 24±6 ms; nicorandil, 23±5 ms; propranolol, 23±5 ms) (Fig 5B).

View larger version (22K): [in this window] [in a new window]   Figure 5. Plots of changes in dispersion of MAPD90 during constant atrial pacing (CL, 600 ms) in control state, during epinephrine infusion (Epin, 0.1 µg · kg-1 · min-1), after nicorandil injection (0.1 mg/kg) during epinephrine (Nic+Epin), and after addition of propranolol injection (0.1 mg/kg) during epinephrine (Prop+Epin) in 6 patients with congenital form of LQT1 syndrome (A) and 8 control patients (B).

T-Wave Morphology and QT Interval
The QT interval was significantly longer in patients with the congenital form of LQT1 syndrome (n=6) than in control patients (n=8) during constant atrial pacing in the control state (397±23 versus 323±8 ms; P<.0005). In LQT1 patients, epinephrine increased the peak or the late component of T waves in precordial leads and markedly prolonged the QT interval to 443±40 ms (P<.001 versus control state) (Figs 2B, 3B, and 6A). Injection of nicorandil during epinephrine infusion slightly decreased the amplitude of the T wave and shortened the QT interval to 420±29 ms, although this difference did not reach statistical significance (P=.09 versus epinephrine) (Figs 2C, 3C, and 6A). Addition of propranolol during epinephrine infusion further decreased the T-wave amplitude and completely reversed the effect of epinephrine in prolonging the QT interval (394±18 ms, P=.1 versus nicorandil) (Figs 2D, 3D, and 6A). In control patients, epinephrine also prolonged the QT interval to 335±8 ms (P<.0005 versus control state). However, the prolongation of the QT interval in control patients was much smaller than that in LQT1 patients (difference in the mean QT interval before and after epinephrine, 46 versus 12 ms), and the T-wave morphology was not changed in control patients as in LQT1 patients. Injection of nicorandil and addition of propranolol during epinephrine infusion did not change the T-wave morphology or the QT interval in control patients (nicorandil, 334±5 ms; propranolol, 328±9 ms) (Fig 6B).

View larger version (21K): [in this window] [in a new window]   Figure 6. Plots of changes in QT interval during constant atrial pacing (CL, 600 ms) in control state, during epinephrine infusion (Epin, 0.1 µg · kg-1 · min-1), after nicorandil injection (0.1 mg/kg) during epinephrine (Nic+Epin), and after addition of propranolol injection (0.1 mg/kg) during epinephrine (Prop+Epin) in 6 patients with congenital form of LQT1 syndrome (A) and 8 control patients (B).

Early Afterdepolarizations
In the control state, no EADs were recorded in any patients with congenital LQT1 syndrome. Epinephrine induced EADs in 2 of the 6 patients with LQT1 syndrome (two recording sites). The EADs were recorded at the right ventricular outflow tract in patient 1 (Fig 2B) and at the LV lateral wall in patient 6 (Fig 3B). Injection of nicorandil during epinephrine infusion abolished the EADs in patient 6 (Fig 3C), whereas addition of propranolol during epinephrine infusion eliminated the EADs in patient 1 (Fig 2D). The 2 patients in whom EADs were recorded had longer MAPD₉₀ during both the control state and epinephrine infusion and showed greater response to nicorandil. Recordings of EADs were stable during the same protocol, and the shape and amplitude of EADs were constant during constant atrial pacing (constant RR interval) in the LQT1 syndrome. Moreover, the amplitude of EADs was bradycardia-dependent and increased after a long preceding RR interval after atrial pacing. These characteristics of EADs were consistent with those of experimentally induced EADs.

No EADs were recorded during the entire protocol in any control patients.

Ventricular Arrhythmias
In the control state, there were no ventricular arrhythmias in any patients with congenital LQT1 syndrome. Epinephrine induced VPCs in 2 patients with LQT1 syndrome in whom EADs were induced by epinephrine. The morphology of the VPCs showed right bundle-branch block pattern with right-axis deviation in patient 1 and right bundle-branch block pattern with left-axis deviation in patient 6, suggesting that the VPCs originated near the LV outflow tract and the LV inferior wall, respectively. Injection of nicorandil during epinephrine infusion abolished the VPCs as well as the EADs in patient 6, whereas addition of propranolol during epinephrine infusion eliminated the VPCs and EADs in patient 1.

There were no VPCs during the entire protocol in any control patients.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Catecholamine-Induced Repolarization Abnormalities and Effects of K⁺ Channel Openers and ß-Blockers in Congenital Form of LQT1 Syndrome
Sympathetic stimulation or catecholamines are well known to produce paradoxical QT prolongation and TdP, which are often linked to syncope or sudden cardiac death in patients with congenital LQTS.^{21 22} Among three forms of the congenital LQTS caused by ion channel mutations, cardiac events (cardiac arrhythmias and sudden cardiac death) are more likely to be associated with adrenergic factors (defined as physical and emotional stress) in the LQT1 syndrome than in either the LQT2 or LQT3 syndrome.^{23 24 25} Commensurate with this, ß-blockers were reported to reduce cardiac events dramatically in LQT1 syndrome.²⁶ Recent genetic linkage analysis studies have shown that a mutation in KvLQT1, which is responsible for LQT1 syndrome, altered the effect of the coexpression of minK and KvLQT1, which resulted in an impairment in the I_Ks current.^{4 5} ß-Adrenergic stimulation increases inward current through I_Ca-L and outward repolarizing I_Ks and I_Cl current.^{27 28} A net increase of outward repolarizing current, because of a greater increase in I_Ks and I_Cl than in I_Ca-L, is usually encountered in response to adrenergic stimulation, and this mechanism is thought to be responsible for the abbreviation of APD and QT interval under normal conditions. Therefore, a lack of increase in I_Ks could offset this balance and account for failure of adrenergic stimulation to abbreviate APD and QT interval appropriately in LQT1 syndrome.²⁹ Several experimental studies have suggested that inward current through I_Ca-L³⁰ or through sodium-calcium exchange³¹ was responsible for the development of EADs. Thus, adrenergic stimulation may easily create the substrate for EAD-induced triggered activity in LQT1 syndrome in which APD remains prolonged.³⁰

In the present study, epinephrine prolonged the MAPD₉₀ and QT interval and increased the dispersion of MAPD₉₀ much more in patients with congenital LQT1 syndrome than in control patients. Epinephrine also induced EADs and VPCs in 2 of the 6 patients with LQT1 syndrome but not in control patients. In the continued presence of epinephrine, nicorandil abbreviated the MAPD₉₀ and QT interval, decreased the dispersion of MAPD₉₀, and abolished EADs as well as VPCs in 1 of the 2 patients.

Nicorandil, which increases outward potassium current through I_KATP, was found to shorten APD and to suppress EADs induced by cesium chloride in in vitro^{32 33} and in vivo³⁴ experimental studies. Two other I_KATP openers, pinacidil and cromakalim, were also reported to effectively suppress EADs and ventricular arrhythmias in the long-QT models produced by cesium chloride,³⁵ clofilium,³⁶ or Bay K 8644.³⁷ Recently, several groups used MAP recordings and showed the effect of nicorandil in decreasing MAP duration and abolishing EADs.^{38 39 40} Our data as well as those in the previous studies suggest that I_KATP openers increase net outward repolarizing current even in case of a defect of I_Ks current during adrenergic stimulation to improve repolarization abnormalities in the congenital form of LQT1 syndrome with KvLQT1 defect.

Propranolol in addition to nicorandil completely reversed the effect of epinephrine in prolonging the MAPD₉₀ and QT interval, increasing the dispersion of MAPD₉₀, and inducing EADs as well as VPCs. The effect of ß-blockers is likely to be mediated by decreasing I_Ca-L as well as preventing catecholamine from binding to ß-adrenergic receptors and is different from that of I_KATP openers. Moreover, because the effect of intravenous injection of nicorandil is relatively short (half-life, 5 to 10 minutes), the effect of nicorandil was likely to be very small at the time that the effect of propranolol was examined. These results support the dramatic effect of ß-blockers in reducing cardiac events in patients with the congenital form of LQT1 syndrome.

Mechanism of Long QT and TdP and Effect of K⁺ Channel Openers
TdP is an atypical polymorphic ventricular tachycardia most often associated with QT prolongation in both congenital and acquired forms of LQTS. Several experimental^{41 42} and clinical observations using MAPs^{12 13 14 16 38 39 40} suggested a significant role for EAD-induced triggered activity in the genesis of TdP. El-Sherif et al⁴³ recently used high-resolution tridimensional isochronal maps of activation and repolarization patterns and showed that the initial beat of the TdP appeared to arise from a focal subendocardial site, whereas subsequent beats were due mainly to reentrant excitation. Antzelevitch and coworkers^{44 45} used isolated arterially perfused canine LV wedge preparations and demonstrated the important role of transmural heterogeneity of action potentials in the induction of TdP, suggesting intramural reentry as the basis for the maintenance of TdP. Using MAP recordings, Shimizu et al^{14 46} demonstrated that the initiating beats (VPCs) of TdP were closely related to triggered activity arising from EADs in patients with the congenital form of LQTS.

In the present study, epinephrine infusion induced EADs as well as VPCs in 2 of 6 patients with LQT1 syndrome. The recording site of the EADs (right ventricular outflow tract and LV lateral wall, respectively) was relatively close to the origin of the VPCs (LV outflow tract and LV inferior wall, respectively), which was estimated by the morphology of the VPCs, although a direct relationship between the EADs and the VPCs could not be demonstrated. Moreover, nicorandil simultaneously eliminated the EADs and VPCs in 1 of the 2 patients (patient 6), whereas additional propranolol did the same in another (patient 1). In addition, both nicorandil and propranolol decreased the dispersion of MAPD₉₀. These results suggest that the epinephrine-induced VPCs were related to the EADs. Our data also suggest that the effect of K⁺ channel openers and ß-blockers on ventricular arrhythmias may be due to (1) suppression of EAD-induced triggered activity responsible for the spontaneous premature beats that precipitate TdP and/or (2) reduction of dispersion of repolarization, which leads to elimination of the substrate for reentry.

Study Limitations
There are several limitations in the present study. The first is the possibility that the EADs recorded in the MAPs represent artifacts. A recent computer simulation study suggested that apparent EADs recorded by the MAPs may reflect marked prolongation of APD in M cells with normal APD in the endocardium, in the absence of EADs in either tissue.⁴⁷ However, recordings of prolonged MAP duration including EADs reflect the existence of prolonged APD at a region near the MAP electrode, so they enable us at least to evaluate the increased dispersion of repolarization. Second, the present study demonstrated the effects of intravenous nicorandil in improving repolarization abnormalities in the congenital form of LQT1 syndrome. Further studies are needed to decide the efficacy of chronic oral therapy of K⁺ channel openers in suppressing TdP and sudden cardiac death in the long-QT syndrome. Third, we were not able to examine the effect of nicorandil in the presence of propranolol. Because ß-blockers are the first line of therapy, especially in the LQT1 syndrome, it is also important to know whether nicorandil offers any effects in addition to those of propranolol.

	Selected Abbreviations and Acronyms

 

APD = action potential duration CL = cycle length EAD = early afterdepolarization ICa-L = L-type calcium channel ICl = chloride channel IKATP = ATP-sensitive potassium channel IKr = rapidly activating component of delayed rectifier potassium current IKs = slowly activating component of delayed rectifier potassium current LQTS = long-QT syndrome LV = left ventricular MAP = monophasic action potential MAPD90 = MAP duration determined at 90% repolarization QTc = corrected QT interval TdP = torsade de pointes VPC = ventricular premature complex

	Acknowledgments

 
This study was supported in part by a grant from the Japanese Cardiovascular Research Foundation by a Bayer Cardiovascular Disease Research Scholarship, Osaka, Japan. We are indebted to Drs Peter J. Schwartz and Arthur J. Moss for their review of and thoughtful comments concerning the manuscript as well as their coordination with the genotyping studies for our patients.

	Footnotes

 
Guest editor for this article was Hein J.J. Wellens, Maastricht, The Netherlands.

Presented in part at the 68th Scientific Sessions of the American Heart Association, Anaheim, Calif, November 14, 1995, and published in abstract form (Circulation. 1995;92[suppl I]:I-275).

Received October 13, 1997; revision received December 8, 1997; accepted December 12, 1997.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Wang Q, Shen J, Splawski I, Atkinson DL, Li ZZ, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805–811.[Medline] [Order article via Infotrieve]

2. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795–803.[Medline] [Order article via Infotrieve]

3. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, Van Raay TJ, Shen J, Timothy KW, Vincent GM, De Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12:17–23.[Medline] [Order article via Infotrieve]

4. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. Coassembly of KvLQT1 and minK (IsK) proteins to form cardiac I_Ks potassium channel. Nature. 1996;384:80–83.[Medline] [Order article via Infotrieve]

5. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. KvLQT1 and IsK (minK) proteins associate to form the I_Ks cardiac potassium current. Nature. 1996;384:78–80.[Medline] [Order article via Infotrieve]

6. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the I_Kr potassium channel. Cell. 1995;81:299–307.[Medline] [Order article via Infotrieve]

7. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantù F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LSK, Colatsky TJ. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na⁺ channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 1995;92:3381–3386.[Abstract/Free Full Text]

8. Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, Keating MT, Mason JW. Genetically defined therapy of inherited long-QT syndrome: correction of abnormal repolarization by potassium. Circulation. 1996;94:1018–1022.[Abstract/Free Full Text]

9. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993;88:782–784.[Free Full Text]

10. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH, Keating MT, MacCluer JW, Timothy KW. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995;92:2929–2934.[Abstract/Free Full Text]

11. Franz MR, Chin MC, Sharkey HR, Griffin JC, Scheinman MM. A new single catheter technique for simultaneous measurement of action potential duration and refractory period in vivo. J Am Coll Cardiol. 1990;16:878–886.[Abstract]

12. Ohe T, Kurita T, Aihara N, Kamakura S, Matsuhisa M, Shimomura K. Electrocardiographic and electrophysiologic studies in patients with torsades de pointes: role of monophasic action potentials. Jpn Circ J. 1990;54:1323–1330.[Medline] [Order article via Infotrieve]

13. Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, Kamakura S, Matsuhisa M, Shimomura K. Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation. 1991;84:1915–1923.[Abstract/Free Full Text]

14. Shimizu W, Ohe T, Kurita T, Kawade M, Arakaki Y, Aihara N, Kamakura S, Kamiya T, Shimomura K. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol. 1995;26:1299–1309.[Abstract]

15. Hirao H, Shimizu W, Kurita T, Suyama K, Aihara N, Kamakura S, Shimomura K. Frequency-dependent electrophysiologic properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol. 1996;28:1269–1277.[Abstract]

16. Kurita T, Ohe T, Shimizu W, Suyama K, Takaki H, Aihara N, Kamakura S, Shimomura K. Early afterdepolarization like activity in patients with class IA induced long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol. 1997;20:695–705.[Medline] [Order article via Infotrieve]

17. Shimizu W, Kurita T, Suyama K, Aihara N, Kamakura S, Shimomura K. Reverse use dependence of human ventricular repolarization by chronic oral sotalol in monophasic action potential recordings. Am J Cardiol. 1996;77:1004–1008.[Medline] [Order article via Infotrieve]

18. Ben-David J, Zipes DP. Differential response to right and left ansae subclaviae stimulation of early afterdepolarizations and ventricular tachycardia induced by cesium in dogs. Circulation. 1988;78:1241–1250.[Abstract/Free Full Text]

19. Browne KF, Zipes DP, Heger JJ, Prystowsky EN. Influence of the autonomic nervous system on the Q-T interval in man. Am J Cardiol. 1982;50:1099–1103.[Medline] [Order article via Infotrieve]

20. Franz MR, Swerdlow CD, Liem LB, Schaefer J. Cycle length dependence of human action potential duration in vivo: effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies. J Clin Invest. 1988;82:972–979.

21. Schwartz PJ. The idiopathic long QT syndrome: progress and questions. Am Heart J. 1985;109:399–411.[Medline] [Order article via Infotrieve]

22. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer JW, Hall WJ, Weitkamp LR, Vincent GM, Garson A, Robinson JL, Benhorin J, Choi S. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991;84:1136–1144.[Abstract/Free Full Text]

23. Timothy KW, Zhang L, Meyer KJ, Vincent GM. Differences in precipitators of cardiac arrest and sudden death in chromosome 11 versus 7 genotype long QT syndrome patients. Circulation. 1996;94(suppl I):I-204. Abstract.

24. Ali RH, Zareba W, Rosero SZ, Moss AJ, Schwartz PJ, Benhorin J, Priori SG, Robinson JL, Locati EH. Adrenergic triggers and non-adrenergic factors associated with cardiac events in long QT syndrome patients. Pacing Clin Electrophysiol. 1997;20:1072. Abstract.

25. Schwartz PJ, Moss AJ, Priori SG, Wang Q, Lehmann MH, Timothy K, Denjoy IF, Haverkamp W, Guicheney P, Paganini V, Scheinman MM, Karnes PS. Gene-specific influence on the triggers for cardiac arrest in the long QT syndrome. Circulation. 1997;96(suppl I):I-212. Abstract.

26. Vincent GM, Fox J, Zhang L, Timothy KW. Beta-blockers markedly reduce risk and syncope in KVLQT1 long QT patients. Circulation. 1996;94(suppl I):I-204. Abstract.

27. Hume JR, Harvey RD. Chloride conductance pathways in heart. Am J Physiol. 1991;261:C399–C412.[Abstract/Free Full Text]

28. Zygmunt AC. Intracellular calcium activates chloride current in canine ventricular myocytes. Am J Physiol. 1994;267:H1984–H1995.[Abstract/Free Full Text]

29. Roden DM, Lazzara R, Rosen MR, Schwartz PJ, Towbin JA, Vincent GM, Antzelevitch C, Brown AM, Colatsky TJ, Crampton RS, Kass RS, Moss AJ, Sanguinetti MC, Zipes DP, for the SADS Foundation Task Force on LQTS. Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions. Circulation. 1996;94:1996–2012.[Abstract/Free Full Text]

30. January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block: a role for L-type Ca²⁺ current. Circ Res. 1989;64:977–990.[Abstract/Free Full Text]

31. Szabo B, Sweidan R, Rajagopalan C, Lazzara R. Role of Na⁺:Ca²⁺ exchange current in Cs⁺-induced early afterdepolarizations in Purkinje fibers. J Cardiovasc Electrophysiol. 1994;5:933–944.[Medline] [Order article via Infotrieve]

32. Imanishi S, Arita M, Aomine M, Kiyosue T. Antiarrhythmic effects of nicorandil on canine Purkinje fibers. J Cardiovasc Pharmacol. 1984;6:772–779.[Medline] [Order article via Infotrieve]

33. Lathrop DA, Nanasi PP, Varro A. In vitro cardiac models of dog Purkinje fibre triggered and spontaneous electrical activity: effects of nicorandil. Br J Pharmacol. 1990;99:119–123.[Medline] [Order article via Infotrieve]

34. Takahashi N, Ito M, Saikawa T, Arita M. Nicorandil suppresses early afterdepolarisation and ventricular arrhythmias induced by caesium chloride in rabbits in vivo. Cardiovasc Res. 1991;25:445–452.[Abstract/Free Full Text]

35. Fish FA, Prakash C, Roden DM. Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activator. Circulation. 1990;82:1362–1369.[Abstract/Free Full Text]

36. Carlsson L, Abrahamsson C, Drews C, Duker G. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization in the rabbit. Circulation. 1992;85:1491–1500.[Abstract/Free Full Text]

37. Spinelli W, Sorota S, Siegel M, Hoffman BF. Antiarrhythmic actions of the ATP-regulated K⁺ current activated by pinacidil. Circ Res. 1991;68:1127–1137.[Abstract/Free Full Text]

38. Shimizu W, Kurita T, Arakaki Y, Aihara N, Kamiya T, Shimomura K. Effects of K⁺ channel opener on repolarization abnormalities demonstrated by monophasic action potential in patients with long QT syndrome. Circulation. 1995;92(suppl I):I-275. Abstract.

39. Sato T, Hata Y, Yamamoto M, Morita H, Mizuo K, Yamanari H, Saito D, Ohe T. Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome. J Cardiovasc Electrophysiol. 1995;6:279–282.[Medline] [Order article via Infotrieve]

40. Chinushi M, Aizawa Y, Furushima H, Inuzuka H, Ojima K, Shibata A. Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome. Jpn Heart J. 1995;36:477–481.[Medline] [Order article via Infotrieve]

41. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res. 1986;56:857–867.[Abstract/Free Full Text]

42. Davidenko JM, Cohen L, Goodrow RJ, Antzelevitch C. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers: effects of stimulation rate, potassium, and magnesium. Circulation. 1989;79:674–686.[Abstract/Free Full Text]

43. El-Sherif N, Caref EB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ Res. 1996;79:474–492.[Abstract/Free Full Text]

44. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT and torsade de pointes. J Am Coll Cardiol. 1996;28:1836–1848.[Abstract]

45. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation. 1997;96:2038–2047.[Abstract/Free Full Text]

46. Shimizu W, Ohe T, Kurita T, Tokuda T, Shimomura K. Epinephrine-induced ventricular premature complexes due to early afterdepolarizations and effects of verapamil and propranolol in a patient with congenital long QT syndrome. J Cardiovasc Electrophysiol. 1994;5:438–444.[Medline] [Order article via Infotrieve]

47. Antzelevitch C, Sicouri S, Lukas A, Nesterenko VV, Liu DW, Di Diego JM. Regional differences in the electrophysiology of ventricular cells: physiological and clinical implications. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 1995:228–245.

This article has been cited by other articles:

				T. G. Diness, Y.-H. Yeh, X. Y. Qi, D. Chartier, Y. Tsuji, R. S. Hansen, S.-P. Olesen, M. Grunnet, and S. Nattel Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome Cardiovasc Res, July 1, 2008; 79(1): 61 - 69. [Abstract] [Full Text] [PDF]

				M. Viitasalo, L. Oikarinen, H. Swan, H. Vaananen, J. Jarvenpaa, H. Hietanen, J. Karjalainen, and L. Toivonen Effects of Beta-Blocker Therapy on Ventricular Repolarization Documented by 24-h Electrocardiography in Patients With Type 1 Long-QT Syndrome J. Am. Coll. Cardiol., August 15, 2006; 48(4): 747 - 753. [Abstract] [Full Text] [PDF]

				W. Shimizu The long QT syndrome: Therapeutic implications of a genetic diagnosis Cardiovasc Res, August 15, 2005; 67(3): 347 - 356. [Abstract] [Full Text] [PDF]

				J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF]

				R. Balasubramaniam, A. A Grace, R. C Saumarez, J. I Vandenberg, and C. L-H Huang Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1 J. Physiol., October 15, 2003; 552(2): 535 - 546. [Abstract] [Full Text] [PDF]

				S. Yong, X. Tian, and Q. Wang LQT4 Gene: The "Missing" Ankyrin Mol. Interv., May 1, 2003; 3(3): 131 - 136. [Abstract] [Full Text] [PDF]

				X. H.T. Wehrens, M. A. Vos, P. A. Doevendans, and H. J.J. Wellens Novel Insights in the Congenital Long QT Syndrome Ann Intern Med, December 17, 2002; 137(12): 981 - 992. [Abstract] [Full Text] [PDF]

				M. Chinushi, H. Kasai, M. Tagawa, T. Washizuka, Y. Hosaka, Y. Chinushi, and Y. Aizawa Triggers of ventricular tachyarrhythmias and therapeutic effects of nicorandil in canine models of LQT2 and LQT3 syndromes J. Am. Coll. Cardiol., August 7, 2002; 40(3): 555 - 562. [Abstract] [Full Text] [PDF]

				X. Xu, J. J. Salata, J. Wang, Y. Wu, G.-X. Yan, T. Liu, R. A. Marinchak, and P. R. Kowey Increasing IKs corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H664 - H670. [Abstract] [Full Text] [PDF]

				T. Noda, H. Takaki, T. Kurita, K. Suyama, N. Nagaya, A. Taguchi, N. Aihara, S. Kamakura, K. Sunagawa, K. Nakamura, et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome Eur. Heart J., June 2, 2002; 23(12): 975 - 983. [Abstract] [Full Text] [PDF]

				Y. Tanabe, M. Inagaki, T. Kurita, N. Nagaya, A. Taguchi, K. Suyama, N. Aihara, S. Kamakura, K. Sunagawa, K. Nakamura, et al. Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome J. Am. Coll. Cardiol., March 1, 2001; 37(3): 911 - 919. [Abstract] [Full Text] [PDF]

				W. Shimizu and C. Antzelevitch Effects of a K+ Channel Opener to Reduce Transmural Dispersion of Repolarization and Prevent Torsade de Pointes in LQT1, LQT2, and LQT3 Models of the Long-QT Syndrome Circulation, August 8, 2000; 102(6): 706 - 712. [Abstract] [Full Text] [PDF]

				C.-E. Chiang and D. M. Roden The long QT syndromes: genetic basis and clinical implications J. Am. Coll. Cardiol., July 1, 2000; 36(1): 1 - 12. [Abstract] [Full Text] [PDF]

				P. G.A. Volders, M. A. Vos, B. Szabo, K. R. Sipido, S.H.M. de Groot, A. P.M. Gorgels, H. J.J. Wellens, and R. Lazzara Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts Cardiovasc Res, June 1, 2000; 46(3): 376 - 392. [Full Text] [PDF]

				W. Shimizu and C. Antzelevitch Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome J. Am. Coll. Cardiol., March 1, 2000; 35(3): 778 - 786. [Abstract] [Full Text] [PDF]

				Y Fujimoto, H Morita, K K Fukushima, and T Ohe Nicorandil abolished repolarisation alternans in a patient with idiopathic long QT syndrome Heart, November 1, 1999; 82(5): 8e - 8. [Abstract] [Full Text]

				P. C Viswanathan and Y. Rudy Pause induced early afterdepolarizations in the long QT syndrome: a simulation study Cardiovasc Res, May 1, 1999; 42(2): 530 - 542. [Abstract] [Full Text] [PDF]

				W. Shimizu and C. Antzelevitch Cellular and Ionic Basis for T-Wave Alternans Under Long-QT Conditions Circulation, March 23, 1999; 99(11): 1499 - 1507. [Abstract] [Full Text] [PDF]

				W. Shimizu and C. Antzelevitch Cellular Basis for the ECG Features of the LQT1 Form of the Long-QT Syndrome : Effects of ß-Adrenergic Agonists and Antagonists and Sodium Channel Blockers on Transmural Dispersion of Repolarization and Torsade de Pointes Circulation, November 24, 1998; 98(21): 2314 - 2322. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shimizu, W. Articles by Shimomura, K. Search for Related Content PubMed PubMed Citation Articles by Shimizu, W. Articles by Shimomura, K. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB EPINEPHRINE NICOTINAMIDE